• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Shockwave Medical Reports First Quarter 2024 Financial Results

    5/6/24 4:05:00 PM ET
    $JNJ
    $SWAV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $JNJ alert in real time by email

    SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024.

    "The solid growth in the first quarter across geographies and products is a testament to the continued demand for our innovative solutions, driven by the unrelenting and extraordinary performance of our global Shockwave teams," said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. "Our team is looking forward to continuing our mission as part of Johnson & Johnson and to working together to bring our life-changing therapies to even more patients across the globe."

    First Quarter 2024 Financial Results

    Revenue for the first quarter ended March 31, 2024, was $218.8 million, a 36% increase from $161.1 million in the same period of 2023. The growth in revenue was primarily driven by increased adoption of Shockwave products in both the United States and internationally.

    Gross profit for the first quarter of 2024 was $190.6 million compared to $140.0 million for the first quarter of 2023. Gross margin percentage was 87% for the three months ended March 31, 2024, consistent with gross margin for the three months ended March 31, 2023.

    Total operating expenses for the first quarter of 2024 were $148.2 million, a 48% increase from $100.2 million in the first quarter of 2023. The increase was primarily driven by sales force expansion and higher headcount to support the growth of the business.

    Net income for the first quarter of 2024 was $55.3 million, compared to net income of $39.1 million in the same period of 2023. Basic and diluted net income per share for the first quarter of 2024 was $1.48 and $1.44, respectively.

    Adjusted EBITDA improved by approximately 19% to $68.5 million, in the first quarter of 2024, compared to adjusted EBITDA of $57.5 million in the first quarter of 2023. Adjusted EBITDA is a non-GAAP measure.

    Cash, cash equivalents and short-term investments totaled $1,029.2 million as of March 31, 2024.

    2024 Financial Guidance

    Given the proposed acquisition of Shockwave Medical by Johnson & Johnson (NYSE:JNJ), Shockwave Medical is withdrawing its full year 2024 guidance, previously issued on February 15, 2024.

    Conference Call

    Given the proposed acquisition of Shockwave Medical by Johnson & Johnson (NYSE:JNJ), Shockwave Medical will not be hosting the previously scheduled earnings conference call today.

    About Shockwave Medical, Inc.

    Shockwave Medical is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic cardiovascular disease by safely using sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly improved patient outcomes. Shockwave Medical has also recently acquired the Reducer, which is under clinical investigation in the United States and is CE Marked in the European Union and the United Kingdom. By redistributing blood flow within the heart, the Reducer is designed to provide relief to the millions of patients worldwide suffering from refractory angina. Learn more at www.shockwavemedical.com.

    Forward-Looking Statements

    This press release contains statements relating to our expectations, projections, beliefs, and prospects, which are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue," and similar expressions, and the negative of these terms. Forward-looking statements in this press release include, but are not limited to, statements regarding our pending acquisition by Johnson & Johnson, our business strategy and plans, our objectives for future operations and financial performance and other matters. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware.

    If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Risks and uncertainties include, but are not limited to: the risk that the closing conditions for the pending acquisition will not be satisfied, including the risk that clearance under the Hart-Scott-Rodino Antitrust Improvements Act or other applicable antitrust laws will not be obtained; uncertainty as to the percentage of our stockholders that will vote to approve the proposed transaction; the possibility that the transaction will not be completed in the expected timeframe or at all; potential adverse effects to our business or the business of Johnson & Johnson during the pendency of the transaction, such as employee departures or distraction of management from business operations; the risk of stockholder litigation relating to the transaction, including resulting expense or delay; the potential that the expected benefits and opportunities of the acquisition, if completed, may not be realized or may take longer to realize than expected; challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new products; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; economic conditions, including currency exchange and interest rate fluctuations; the risks associated with global operations; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including tax laws and global health care reforms; adverse litigation or government action; changes in behavior and spending patterns or financial distress of purchasers of health care services and products; and trends toward health care cost containment. These factors, as well as others, are discussed in our filings with the Securities and Exchange Commission (SEC), including in the sections titled "Risk Factors" in our most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q, and in our other reports filed with the SEC. Except to the extent required by law, we do not undertake to update any of these forward-looking statements after the date hereof to conform these statements to actual results or revised expectations.

    Use of Non-GAAP Financial Measures

    This press release contains supplemental financial information determined by methods other than in accordance with accounting principles generally accepted in the United States (GAAP), including references to adjusted EBITDA, a non-GAAP financial measure that excludes from net income the effects of income tax (benefit) provision, other (expense) income, net, interest expense, interest income, income (loss) from equity method investment, depreciation and amortization, and stock-based compensation. We believe the presentation of adjusted EBITDA is useful as it provides visibility to our underlying continuing operating performance by excluding the impact of certain items that are non-cash in nature or not related to our core business operations.

    Our definition of adjusted EBITDA may differ from similarly titled measures used by others. Adjusted EBITDA should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. Because adjusted EBITDA excludes the effect of items that increase or decrease our reported results of operations, management strongly encourages investors to review, when they become available, our consolidated financial statements and publicly filed reports in their entirety. A reconciliation of adjusted EBITDA to net income has been provided in the financial statement tables included in this press release, and investors are encouraged to review the reconciliation.

    Media Contact:

    Scott Shadiow

    +1.317.432.9210

    [email protected]

    Investor Contact:

    Debbie Kaster

    [email protected]

    SHOCKWAVE MEDICAL, INC.

    Balance Sheet Data

    (in thousands)

          
      March 31,

    2024
     December 31,

    2023

      (Unaudited)   
    ASSETS    
    CURRENT ASSETS:     
    Cash and cash equivalents $281,674  $328,422
    Short-term investments  747,559   662,132
    Accounts receivable, net  124,440   114,552
    Inventory  111,215   107,587
    Prepaid expenses and other current assets  10,462   12,567
    Total current assets  1,275,350   1,225,260
    Operating lease right-of-use assets  34,919   29,707
    Property and equipment, net  78,693   68,923
    Equity method investment  2,356   1,643
    Intangible assets, net  91,960   92,857
    Goodwill  39,568   39,568
    Deferred tax assets  111,900   99,169
    Other assets  9,001   9,436
    TOTAL ASSETS $1,643,747  $1,566,563
    LIABILITIES AND STOCKHOLDERS' EQUITY     
    CURRENT LIABILITIES:    
    Accounts payable $9,843  $8,868
    Accrued liabilities  78,838   91,696
    Lease liability, current portion  3,653   3,641
    Total current liabilities  92,334   104,205
    Lease liability, noncurrent portion  40,336   35,103
    Convertible debt, noncurrent portion  732,810   731,863
    Related party contract liability, noncurrent portion  12,273   12,273
    Deferred tax liabilities  3,609   3,609
    Long-term income tax liability  2,969   1,526
    Other liabilities  7,659   9,307
    TOTAL LIABILITIES  891,990   897,886
    STOCKHOLDERS' EQUITY:    
    Common stock  38   37
    Additional paid-in capital  586,017   557,882
    Accumulated other comprehensive (loss) income  (109)  293
    Retained earnings  165,811   110,465
    TOTAL STOCKHOLDERS' EQUITY  751,757   668,677
    TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $1,643,747  $1,566,563



    SHOCKWAVE MEDICAL, INC.
    Statement of Operations Data
    (Unaudited)
    (in thousands, except share and per share data)
     
      Three Months Ended
      March 31,
       2024   2023 
    Revenue:    
    Product revenue $218,805  $161,066 
    Cost of revenue:    
    Cost of product revenue  28,207   21,066 
    Gross profit  190,598   140,000 
    Operating expenses:    
    Research and development  44,466   26,971 
    Sales and marketing  74,492   54,011 
    General and administrative  29,233   19,204 
    Total operating expenses  148,191   100,186 
    Income from operations  42,407   39,814 
    Income (loss) from equity method investment  713   (823)
    Interest income  12,318   1,740 
    Interest expense  (2,943)  (636)
    Other (expense) income, net  (2,496)  642 
    Net income before taxes  49,999   40,737 
    Income tax (benefit) provision  (5,347)  1,612 
    Net income $55,346  $39,125 
    Net income per share, basic $1.48  $1.07 
    Net income per share, diluted $1.44  $1.03 
    Shares used in computing net income per share, basic  37,284,946   36,427,263 
    Shares used in computing net income per share, diluted  38,472,013   37,979,448 



    SHOCKWAVE MEDICAL, INC.
    Reconciliation of GAAP Net Income to Adjusted EBITDA
    (Unaudited)
    (in thousands)
     
      Three Months Ended
      March 31,
       2024   2023 
    GAAP Net Income $55,346  $39,125 
    Non-GAAP Adjustments    
    Income tax (benefit) provision  (5,347)  1,612 
    Other expense (income), net  2,496   (642)
    Interest expense  2,943   636 
    Interest income  (12,318)  (1,740)
    (Income) loss from equity method investment  (713)  823 
    Depreciation and amortization  3,109   1,708 
    Stock-based compensation expense  22,937   15,967 
    Adjusted EBITDA $68,453  $57,489 


    Primary Logo

    Get the next $JNJ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JNJ
    $SWAV

    CompanyDatePrice TargetRatingAnalyst
    Johnson & Johnson
    $JNJ
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    Johnson & Johnson
    $JNJ
    12/10/2024$166.00Neutral
    BofA Securities
    Johnson & Johnson
    $JNJ
    11/15/2024$190.00Outperform
    Wolfe Research
    Johnson & Johnson
    $JNJ
    7/23/2024$160.00 → $150.00Outperform → Neutral
    Daiwa Securities
    Johnson & Johnson
    $JNJ
    5/30/2024$160.00Neutral
    Goldman
    Johnson & Johnson
    $JNJ
    4/18/2024$170.00Hold → Buy
    HSBC Securities
    Shockwave Medical Inc.
    $SWAV
    4/5/2024Outperform → Peer Perform
    Wolfe Research
    Shockwave Medical Inc.
    $SWAV
    3/27/2024$368.00Buy
    CL King
    More analyst ratings

    $JNJ
    $SWAV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma

      ODAC recommendation based on the positive progression-free survival and clinical benefit in the Phase 3 AQUILA study If approved, DARZALEX FASPRO® would be the first treatment to potentially delay or prevent progression to multiple myeloma RARITAN, N.J., May 20, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted (6-2) in favor of the benefit-risk profile of single-agent DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of adult patients with high-risk smoldering multiple myeloma (HR-SMM). An application for the approval of DARZALEX FASPRO® for adult patients with H

      5/20/25 6:21:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dean Omar Branham Shirley Recognized Twice Among ALM's 2024 Top 100 Verdicts

      Both decisions benefited plaintiffs harmed by using Johnson & Johnson's Baby Powder National plaintiffs firm Dean Omar Branham Shirley, LLP, has been recognized by ALM and Law.com for securing two of the largest jury verdicts of 2024. Both cases involved claims against pharmaceutical giant Johnson & Johnson (NYSE:JNJ) over its talc-based Baby Powder, which exposed users to asbestos, a known carcinogen. The 29th-ranked case on the ALM list was a $260 million verdict in Oregon on behalf of Kyung Lee, a 49-year-old mother of three who was diagnosed with mesothelioma after lifelong use of J&J's Baby Powder. Jurors awarded $60 million in compensatory damages and $200 million in punitive damag

      5/20/25 12:24:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Statement On $147M Verdict for AMDR Member Innovative Health Against Johnson & Johnson's Biosense Webster Medical Technology Unit

      Association of Medical Device Reprocessors issued the following statement: Friday's unanimous verdict by a federal jury in Santa Ana, California for Innovative Health against Johnson & Johnson (NYSE: JNJ) is a victory for America's hospitals, providers, patients, and the environment. The jury found that Biosense Webster violated federal and state antitrust laws by withholding clinical support to hospitals using Innovative Health's FDA regulated, reprocessed catheters. "For too long, Johnson & Johnson has used tying arrangements and other tactics to interfere with fair competition from lower cost, FDA regulated, reprocessed ‘single-use' devices (SUDs)," said Daniel J. Vukelich, President a

      5/18/25 4:32:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $SWAV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • July 21, 2023 - FDA Roundup: July 21, 2023

      For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

      7/21/23 4:02:23 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

      For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

      5/5/22 4:51:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

      For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

      8/18/21 1:06:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $SWAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Johnson & Johnson downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Johnson & Johnson from Outperform to Market Perform and set a new price target of $153.00

      5/13/25 8:56:13 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities resumed coverage on Johnson & Johnson with a new price target

      BofA Securities resumed coverage of Johnson & Johnson with a rating of Neutral and set a new price target of $166.00

      12/10/24 8:28:42 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Johnson & Johnson with a new price target

      Wolfe Research initiated coverage of Johnson & Johnson with a rating of Outperform and set a new price target of $190.00

      11/15/24 8:10:35 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $SWAV
    Leadership Updates

    Live Leadership Updates

    See more
    • Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

      WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, today announced the appointment of David E. Banko, CPA, a leading expert with three decades of industry experience in market access and health policy, to its leadership team as Global Head of Government Affairs and Patient Access. In this critical role, Mr. Banko will spearhead market access strategies in collaboration with R&D across Tevogen's growing product portfolio in oncology, virology, neurology, and rheumatology to advance and support commercial readines

      3/25/25 1:11:06 PM ET
      $JNJ
      $TVGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations

      Jessica Moore Appointed Group Chief Financial Officer, Johnson & Johnson, Innovative Medicine Johnson & Johnson (NYSE:JNJ) (the "Company") today announced the appointment of Darren Snellgrove to Vice President, Investor Relations. Jessica Moore, who has served as Vice President, Investor Relations since 2021, will assume the role of Group Chief Financial Officer, Johnson & Johnson, Innovative Medicine. The new appointments are effective May 1, 2025, and Mr. Snellgrove as well as Ms. Moore, will continue to report to Johnson & Johnson's Executive Vice President and Chief Financial Officer, Joseph Wolk. "Today's announcement reflects the deep bench of talent within Johnson & Johnson as well

      3/4/25 4:15:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bruker Appoints Laura Francis to its Board of Directors

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

      2/21/25 8:00:00 AM ET
      $BRKR
      $PGNY
      $SIBN
      $SWAV
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Misc Health and Biotechnology Services
      Health Care

    $JNJ
    $SWAV
    Financials

    Live finance-specific insights

    See more
    • Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8%

      Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a 4.8% increase in the quarterly dividend, from $1.24 per share to $1.30 per share, marking the 63rd year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $5.20 per share compared to the previous rate of $4.96 per share. The next quarterly dividend is payable on June 10, 2025 to shareholders of record at the close of business on May 27, 2025. The ex-dividend date is May 27, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, trea

      4/15/25 6:25:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson Reports Q1 2025 Results

      2025 First-Quarter reported sales growth of 2.4% to $21.9 Billion with operational growth of 4.2%* and adjusted operational growth of 3.3%* 2025 First-Quarter earnings per share (EPS) increased to $4.54 which includes the reversal of special charges and adjusted EPS increased to $2.77 or 2.2%* Significant new product pipeline progress including approval of TREMFYA in Crohn's disease, data for RYBREVANT/LAZCLUZE overall survival in non-small cell lung cancer and icotrokinra in plaque psoriasis, and initiation of the clinical trial for a general surgery robotic system, OTTAVA Company increases Full-Year 2025 operational sales2,5 guidance to reflect the addition of CAPLYTA following the

      4/15/25 6:20:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims

      Company has prevailed in 16 of 17 ovarian cases tried in the last 11 years Company will reverse approximately $7 billion from amounts previously reserved for the bankruptcy resolution Today, the U.S. Bankruptcy Court for the Southern District of Texas denied the request by Johnson & Johnson (NYSE:JNJ) (the "Company") subsidiary Red River Talc LLC ("Red River") to confirm its proposed prepackaged bankruptcy plan—notwithstanding that it offered one of the largest settlements ever proposed in a mass tort bankruptcy and was supported by the overwhelming majority of claimants. Rather than pursue a protracted appeal, the Company will return to the tort system to litigate and defeat these merit

      3/31/25 10:20:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $SWAV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      12/12/24 5:27:36 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $SWAV
    SEC Filings

    See more
    • SEC Form 13F-HR filed by Johnson & Johnson

      13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)

      5/7/25 4:47:35 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - JOHNSON & JOHNSON (0000200406) (Filer)

      4/30/25 4:30:48 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Johnson & Johnson

      10-Q - JOHNSON & JOHNSON (0000200406) (Filer)

      4/23/25 4:04:45 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $SWAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Innovative Medicine, R&D Reed John C converted options into 25,255 shares and covered exercise/tax liability with 11,002 shares, increasing direct ownership by 92% to 29,795 units (SEC Form 4)

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      5/5/25 5:10:14 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Woods Eugene A.

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      4/28/25 5:57:54 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director West Nadja

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      4/28/25 5:54:13 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $SWAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Johnson & Johnson

      SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

      4/10/24 5:12:55 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ShockWave Medical Inc. (Amendment)

      SC 13G/A - Shockwave Medical, Inc. (0001642545) (Subject)

      2/13/24 5:13:59 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

      SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

      2/13/24 5:07:58 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care